Piper Sandler raised the firm’s price target on Scholar Rock to $42 from $28 and keeps an Overweight rating on the shares. The firm continues to recommend Scholar Rock shares and is updating its model following the company’s recent financing. Piper continues to believe apitegromab’s Phase 3 SAPPHIRE data, along with long-term follow-up data available from the Phase 2 TOPAZ trial, put Scholar Rock in a good spot for regulatory submission in SMA patients ages 2+, and continues to model approval/launch in Q4 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock price target raised to $38 from $34 at BMO Capital
- Biotech Alert: Searches spiking for these stocks today
- Scholar Rock Holding (SRRK) Stock Rockets Up on Positive Phase 3 Trial Results
- Scholar Rock 10.265M share Secondary priced at $28.25
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz